Peri-Operative Nasal Eradication Therapy Prevents Staphylococcus aureus Surgical Site Infections in Aortoiliac Surgery

Surgical Infections
Jasper C M LangenbergLyckle Van Der Laan

Abstract

Surgical site infections (SSIs) cause considerable morbidity and deaths among patients undergoing vascular surgery. Pre-operative screening and subsequent treatment of nasal Staphylococcus aureus carriers with mupirocin and chlorhexidine reduces the risk of SSIs in cardiothoracic and orthopedic surgery. The aim of this study was to investigate the effect of this screen-and-treat strategy on the development of SSI in patients undergoing aortoiliac surgery. A prospective study was performed that enrolled an intervention cohort comprising all patients undergoing aortoiliac surgery from February 2013 to December 2016. Before surgery, patients were screened for S. aureus nasal carriage and, if positive, were treated with mupirocin nasal ointment and chlorhexidine body washes. The presence of SSI was recorded on the basis of the criteria of the U.S. Centers for Disease Control and Prevention. A historic control group was used, consisting of aortoiliac surgery patients in 2010 who tested positive for S. aureus but received no treatment. A total of 374 patients in the study cohort were screened of whom 75 (20.1%) tested positive for S. aureus. Of these patients, 68 were given eradication therapy. In the 2010 cohort, 22 patients (15.7%)...Continue Reading

References

Jan 1, 1995·The Journal of Infectious Diseases·J A KluytmansH A Verbrugh
Jun 14, 2002·The New England Journal of Medicine·Trish M PerlUNKNOWN Mupirocin And The Risk Of Staphylococcus Aureus Study Team
May 3, 2003·The Journal of Clinical Investigation·Franklin D Lowy
Mar 17, 2004·Annals of Internal Medicine·Heiman F L WertheimHenri A Verbrugh
Jan 19, 2006·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Alexander J KallenRobin J Larson
Aug 26, 2006·The Journal of Hospital Infection·A KonvalinkaI W Fong
Jan 8, 2010·The New England Journal of Medicine·Lonneke G M BodeMargreet C Vos
Jun 1, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C LaurentY Glupczynski
Oct 28, 2011·American Journal of Clinical Pathology·David H SpencerCarey-Ann D Burnham
Jun 12, 2012·PloS One·Jeroen M W DonkerJan A J W Kluytmans
Apr 27, 2016·Seminars in Vascular Surgery·Tazo Inui, Dennis F Bandyk
Aug 17, 2016·PloS One·J C M LangenbergL van der Laan

❮ Previous
Next ❯

Citations

Feb 19, 2020·Journal of Wound Care·Jan StryjaDeborah Xuereb
Feb 10, 2020·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·Nabil ChakféAnders Wanhainen

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay

Software Mentioned

Cytel
SPSS
LogXact

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.